PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of arthrestherBioMed Centralbiomed central web sitesearchsubmit a manuscriptregisterthis articleArthritis Research & Therapy
 
Arthritis Res Ther. 2006; 8(4): 215.
Published online Jun 14, 2006. doi:  10.1186/ar1977
PMCID: PMC1779429
Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data
Christina D Chambers,corresponding author1,2 Zuhre N Tutuncu,3 Diana Johnson,1 and Kenneth L Jones1
1Department of Pediatrics, University of California, San Diego, CA, USA
2Department of Family and Preventive Medicine, University of California, San Diego, CA, USA
3Department of Medicine, University of California, San Diego, CA, USA
corresponding authorCorresponding author.
Christina D Chambers: chchambers/at/ucsd.edu
Abstract
For female patients with rheumatoid arthritis, the availability of a host of new disease modifying antirheumatic drugs has raised important questions about fetal safety if a woman becomes pregnant while she is being treated. In addition, there is limited safety information regarding many of the older medications commonly used to treat rheumatoid arthritis in women of reproductive age. Current summary pregnancy risk information for selected medications used to treat rheumatoid arthritis is reviewed in the context of the pregnancy label category. In addition, the strengths and weaknesses of post-marketing strategies for developing new pregnancy safety information are described.
Articles from Arthritis Research & Therapy are provided here courtesy of
BioMed Central